Zhen-Lin Chen

Zhen-Lin Chen


Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 October 2022 in Aging and disease
Verified
Journal Article
Open access
SZShuo Zhang
Shuo Zhang
ZYZhen Yang
Zhen Yang
ZLZhuo-Ning Li
Zhuo-Ning Li
ZCZhen-Lin Chen
Zhen-Lin Chen
SYShi-Jun Yue
Shi-Jun Yue
YTYu-Ping Tang
Yu-Ping Tang
Since the outbreak, COVID-19 has spread rapidly across the globe due to its high infectivity and lethality. Age appears to be one of the key factors influencing the status and progression of SARS-CoV-2 infection, as multiple reports indicated that the majority of COVID-19 infections and severe cases are elderly. Most people simply assume that the elderly are more susceptible to SARS-CoV-2 than the young, but the mechanism behind it is still open to question. The older and younger people are at similar risk of infection because their infection process is the same and they must be exposed to the virus first. However, whether they will get sick after exposure to the virus and how their disease progresses depend on their immune mechanisms. In older populations, inflammation and immune aging reduce their ability to resist SARS-CoV-2 infection. Meanwhile, under the influence of comorbidities, ACE2 receptor and various cytokines undergo corresponding changes, thus accelerating the entry, replication, and transmission of SARS-CoV-2 in the body, promoting disease progression, and leading to severe illness and even death. In addition, the relatively fragile mental state of the elderly can also affect their timely recovery from COVID-19. Therefore, once older people are infected with SARS-CoV-2, they are more prone to severe illness and death with a poor prognosis, and they should strengthen protection to avoid exposure to the virus.

29 September 2021 in Evidence-Based Complementary and Alternative Medicine
Verified
Journal Article
Open access
PDF file
SZShuo Zhang
Shuo Zhang
ZCZhen-Lin Chen
Zhen-Lin Chen
YTYu-Ping Tang
Yu-Ping Tang
JDJin-Long Duan
Jin-Long Duan
KYKuiwu Yao
Kuiwu Yao
Objective. To systematically evaluate the efficacy and safety of XFZYD for coronary heart disease (CHD). Methods. A comprehensive literature search of randomized controlled trials using XFZYD for CHD was conducted in 10 electronic databases from their establishment to December 20, 2020. The researchers screened the relevant trials in NoteExpress, extracted the data in duplicate independently, assessed the risk of bias in the trials using the Cochrane collaboration tool, and then used Rev Man 5.3 for data analysis. Results. 30 trials with 3126 participants were included for meta-analysis. The results showed that the clinical effects of XFZYD and its combination with chemical drugs (CD) were 1.13 (RR; 1.13; 95 CI, 1.03 to 1.24) and 1.26 (RR; 1.26; 95 CI, 1.20 to 1.32) times those of CD, respectively. And, it could also improve electrocardiogram effect, which was 1.63 (RR; 1.63; 95 CI, 1.04 to 2.53) times that of CD. XFZYD could not only decrease duration of angina pectoris and improve vascular endothelial function but also obviously reduce the TCM syndrome score. When used in combination with CD, it could also lower AF, correct the dyslipidemia, and reduce the blood viscosity. Conclusion. These results demonstrated that XFZYD had great advantages in treating CHD with no obvious adverse reactions. Therefore, it is believed that XFZYD is more suitable for CHD patients with clinical indicators of dyslipidemia, high blood viscosity, or vascular endothelial dysfunction. This study is the first systematic review and meta-analysis with some unique ways, including its comprehensiveness, large-scale search, the novelty of findings, and transparent approach.

25 July 2022 in Frontiers in Public Health
Verified
Journal Article
Open access
SZShuo Zhang
Shuo Zhang
ZYZhen Yang
Zhen Yang
ZCZhen-Lin Chen
Zhen-Lin Chen
SYShi-Jun Yue
Shi-Jun Yue
SZSai Zhang
Sai Zhang
YTYu-Ping Tang
Yu-Ping Tang
Why does COVID-19 continue to spread despite mass vaccination?

12 January 2022 in Evidence-Based Complementary and Alternative Medicine
Verified
Journal Article
Open access
PDF file
SZShuo Zhang
Shuo Zhang
ZYZhen Yang
Zhen Yang
ZCZhen-Lin Chen
Zhen-Lin Chen
ZLZhuo-Ning Li
Zhuo-Ning Li
SYShijun Yue
Shijun Yue
YTYu-Ping Tang
Yu-Ping Tang
Objective. To systematically evaluate the efficacy, safety, and precision of TMTP for COVID-19. Methods. Randomized controlled trials and retrospective studies were searched in 11 electronic databases. This network meta-analysis included trials using TMTP to treat patients with COVID-19. The traditional pairwise meta-analysis was done by using Stata 15, and Bayesian network meta-analysis was done with WinBUGS. Results. 18 trials were included with 2036 participants and 7 drugs. The results showed that LHQW had the most significant effects on improving expectoration, shortness of breath, sore throat, nausea, emesis, inappetence, muscle soreness, and headache, and it could produce the least adverse reactions. XBJ was the best drug for fever, fatigue, and diarrhea, which showed great advantages in lowering WBC levels. XFBD was the most effective drug for cough and chest distress, which had the least exacerbation rate. JHQG was the most effective for rhinobyon and rhinorrhea, while QFPD was the best drug in decreasing CRP levels. Conclusion. This study was the first most large-scale and comprehensive research of TMTP for COVID-19. The results showed that LHQW had good efficacy without obvious adverse reactions. Therefore, we believe that it should be firstly recommended for COVID-19 treatment. In addition, XBJ is recommended for patients with a severe fever, fatigue, and diarrhea, and JHQG is recommended for patients with obvious rhinobyon and rhinorrhea; then, XFBD is recommended for patients with cough and chest tightness as the main manifestation. Our findings will help experts develop new COVID-19 treatment guidelines to better guide clinical medication for protecting the health of COVID-19 patients.

1 January 2022 in Aging and disease
Verified
Journal Article
Open access
SZShuo Zhang
Shuo Zhang
ZYZhen Yang
Zhen Yang
ZCZhen-Lin Chen
Zhen-Lin Chen
ZLZhuo-Ning Li
Zhuo-Ning Li
SYShi-Jun Yue
Shi-Jun Yue
YTYu-Ping Tang
Yu-Ping Tang

1 April 2025 in Guidelines and Standards of Chinese Medicine
Verified
Journal Article
Open access
YWYan Wang
Yan Wang
ZCZhen-Lin Chen
Zhen-Lin Chen
WXWen Xin
Wen Xin
WLWenna Li
Wenna Li
TGTiantian Gao
Tiantian Gao
Objective: To observe the clinical efficacy and safety of traditional Chinese medicine (TCM) detoxifying wash in the treatment of tinea versicolor with gastrointestinal dampness-heat syndrome. Methods: Ninety-three patients with tinea versicolor were randomly divided into observation group (48 cases) and control group (45 cases). This study was a single-blind, randomized controlled trial. The observation group was treated with external application of detoxifying wash, whereas the control group was treated with 1% bifonazole solution. Both groups received treatment for 20 days, with 10 days as one course. The clinical efficacy and adverse reactions were recorded after treatment. Results: After treatment, the observation group showed significant improvement in clinical indicators, including erythema, scales, itching, and skin greasiness. After 10 days of treatment, there was no significant difference in clinical efficacy between the two groups. After 20 days, the cure rate, effective rate, and fungal clearance rate in the observation group were higher than those of the control group, indicating superior clinical efficacy. No significant adverse reactions were observed in either group during treatment. Conclusion: Detoxifying wash is safe and effective in treating tinea versicolor with gastrointestinal dampness-heat syndrome.